Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status
Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status
The aim of this study is to check correlation between CYP2C19 genotype level of clopidogrel
 metabolite in plasma and platelet inhibition status.
THE FIRST PHASE OF THE RESEARCH WILL INVOLVE PATIENTS RECRUITMENT AND INFORMED CONSENT FOR
 GENETIC TESTING.THE MAJORITY OF PATIENTS WILL BE RECRUITED FROM EMERGENCY DEPARTMENT. EVERY
 PATIENT WILL BE ASKED ABOUT HIS AND HIS PARENT'S ETHNICITY (ASHKENASI OR SEPHARDY JEW) AND
 ADDITIONAL DRUGS HE TAKES. IF PATIENT AGREES TO PARTICIPATE IN THE STUDY , HIS BLOOD SAMPLE
 WILL BE COLLECTED FOR 3 KINDS OF TESTS:

 1. GENETIC (FOR CYP450 2C19)

 2. PLATELET MAPPING TEST ( BY THROMBOELASTOGRAPH ASSAY)

 3. CLOPIDOGREL INACTIVE METABOLITE DETERMINATION BY CHROMATOGRAPHIC METHOD
Inclusion Criteria:

 -  > 18 OLD PATIENTS

 -  THAT TAKE CLOPIDOGREL MORE THAN 1 WEEK

 Exclusion Criteria:

 -  PREGNANCY

 -  CHRONIC LIVER DISEASES